Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CN NMPA Guides Pharmas, Research Institutes to Enlarge R&D of Innovative Drugs, High-Quality Generic Drugs
Recommend 49 Positive 84 Negative 35 |
||||
|
||||
|
Huang Guo, deputy director of the National Medical Products Administration (NMPA), recently led a team to Shandong Province, where they visited pharmaceuticals and research institutes to conduct in-depth research on promoting the high-quality development of the pharmaceutical industry. Huang underscored that the NMPA attaches great importance to the R&D of innovative drugs and external cooperation. The drug regulatory units will further optimize the review and approval process; support the introduction of original research drugs for domestic production; and enhance the confidence of multinational companies in investing and developing in China. At the same time, they will continue to improve relevant policies to support and guide enterprises and R&D institutes to increase R&D of innovative drugs and high-quality generic drugs, and actively participate in competition at home and abroad. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
